Good vs. Evil? India rejects Novartis claim on drug improvements

India’s rejection of Novartis’ claim on drug improvements highlights the flexibility of India’s patent laws. Such flexibility stands in sharp contrast to the World Trade Organization’s efforts to set standards for intellectual property regulation (via TRIPS agreement) and has enabled India to become a worldwide producer of cheap drugs. Various health agencies have proclaimed the […]